



RPD.10/1
H2/61/13

5 October 2015

Dear Professor Sarrafzadegan,

I would like to thank you for the valuable contribution made by your institution during its previous period of designation as WHO collaborating centre. I am pleased to inform you that the World Health Organization has re-designated **Isfahan Cardiovascular Research Centre, Isfahan University of Medical Sciences** as a **WHO Collaborating Centre for Research and Training in Cardiovascular Diseases Control, Prevention, and Rehabilitation for Cardiac Patients** under WHO's reference number **IRA-23**.

As previously agreed, **Professor Nizal Sarrafzadegan** will act as Head of the Centre. Should there be any change in the future, I would be grateful if you would inform WHO without delay.

The agreed terms of reference are attached. We wish to emphasize that institutions designated as WHO Collaborating Centres are expected to implement the agreed workplan in a timely manner and to the highest possible standard of quality. Any issue that may affect the implementation of the agreed workplan should be brought to the attention of the WHO responsible officer, **Dr Ibtihal Fadhil**, 00202 22765235, fadhili@who.int and emrgonep@who.int. For information on administrative matters, please visit the WHO website <http://www.who.int/collaboratingcentres/information/en/>

We wish to also emphasize that institutions designated as WHO Collaborating Centres must also comply with the attached *Terms and conditions for WHO collaborating centres*. We wish to draw your particular attention to the fact that the WHO name and emblem may only be used by a WHO Collaborating Centre as described in those terms and conditions.

Finally, please note that institutions designated as WHO Collaborating Centres must complete a short online progress report form once a year. On the anniversary of the designation date, details will be sent to the email address of the Head of the Centre specified in the designation form.

Professor Nizal Sarrafzadegan
Director
Isfahan Cardiovascular Research Centre
Isfahan University of Medical Sciences
Teheran
ISLAMIC REPUBLIC OF IRAN

.... ENCL. As stated above

The designation as a WHO Collaborating Centre will be effective for a period of **4 years**, as from **25 October 2015** and will automatically end on **25 October 2019** unless re-designation has been approved by WHO before that date. During the period of designation, either party may revoke the designation at any time by giving three months advance notice in writing.

Again, I would like to express my appreciation for your past contribution and I look forward to our continuing successful collaboration.

Best Wishes.

Yours sincerely,



Dr Ala Alwan
Regional Director

CC: H.E. The Minister for Foreign Affairs of the Islamic Republic of Iran, Teheran
H.E. The Minister of Foreign Affairs, Ministry of Foreign Affairs, Teheran
Director General for International Relations Department, Ministry of Health and Medical
Education, Teheran
Director General, International Agencies Affairs, Ministry of Foreign Affairs, Teheran
Permanent Mission of the Islamic Republic of Iran to the United Nations Office and
Other International Organizations

**WHO Collaborating Centre for Research and Training in Cardiovascular
Diseases Control, Prevention, and Rehabilitation for Cardiac Patients**

Professor Nizal Sarrafzadegan

Director, Isfahan Cardiovascular Research Centre

Tehran

Islamic Republic of Iran

Phone : (98-311) 3377888/ 3377889

Fax: (98-311) 3373435

E-mail: crc@mui.ac.ir

Web Site : <http://www.crc.mui.ac.ir>

PROPOSED TERMS OF REFERENCE

1. Support WHO in the assessment of salt and fat intake and in the provision of technical support to national health authorities and Member States to develop and implement action plans and the WHO best buys to address these risk factors.
2. Assist WHO in building capacity in Noncommunicable diseases surveillance at national or regional levels
3. Assist WHO in building capacity in the integration of interventions for Noncommunicable diseases and its risk factors prevention and control into primary healthcare.